Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) has earned an average recommendation of “Buy” from the eleven analysts that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $26.33.

Several research analysts have commented on the stock. Zacks Investment Research lowered shares of Aurinia Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, July 24th. BidaskClub raised shares of Aurinia Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, September 11th. HC Wainwright lifted their price objective on shares of Aurinia Pharmaceuticals from $33.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Royal Bank of Canada reaffirmed a “buy” rating on shares of Aurinia Pharmaceuticals in a research note on Thursday, August 13th. Finally, ValuEngine raised shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, August 3rd.

Shares of Aurinia Pharmaceuticals stock traded up $0.58 on Friday, hitting $15.53. 71,397 shares of the company traded hands, compared to its average volume of 1,506,529. The stock has a market capitalization of $1.89 billion, a P/E ratio of -10.68 and a beta of 1.10. The company has a debt-to-equity ratio of 0.03, a quick ratio of 16.22 and a current ratio of 16.22. Aurinia Pharmaceuticals has a 52 week low of $3.52 and a 52 week high of $21.93. The business has a 50-day simple moving average of $14.23 and a 200 day simple moving average of $15.17.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings data on Tuesday, August 11th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.03). Aurinia Pharmaceuticals had a negative net margin of 48,648.11% and a negative return on equity of 41.60%. The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.06 million. Research analysts expect that Aurinia Pharmaceuticals will post -0.9 earnings per share for the current year.

Several institutional investors and hedge funds have recently modified their holdings of the company. Avidity Partners Management LP boosted its stake in shares of Aurinia Pharmaceuticals by 109.4% during the second quarter. Avidity Partners Management LP now owns 2,474,599 shares of the biotechnology company’s stock valued at $40,212,000 after purchasing an additional 1,292,599 shares during the period. Pictet Asset Management Ltd. bought a new stake in shares of Aurinia Pharmaceuticals in the first quarter valued at about $23,446,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Aurinia Pharmaceuticals in the first quarter valued at about $15,653,000. BlackRock Inc. raised its holdings in shares of Aurinia Pharmaceuticals by 7.2% in the first quarter. BlackRock Inc. now owns 931,513 shares of the biotechnology company’s stock valued at $13,516,000 after acquiring an additional 62,202 shares in the last quarter. Finally, Artal Group S.A. raised its holdings in shares of Aurinia Pharmaceuticals by 20.0% in the second quarter. Artal Group S.A. now owns 900,000 shares of the biotechnology company’s stock valued at $14,625,000 after acquiring an additional 150,000 shares in the last quarter. 46.37% of the stock is owned by hedge funds and other institutional investors.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Featured Story: What causes a stock to be most active?

Analyst Recommendations for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.